Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Pfizer made one thing clear this week: It's officially back in the obesity race.

Can Pfizer crash the Lilly and Novo Nordisk weight-loss party?

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

Pfizer weight-loss drug data raises questions about side effects, shares fall

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer’s Experimental Weight Loss Drug Shows Promise as a Once-a-Month Shot

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

Pfizer’s stock fell after mixed response to weight-loss data for drug set to compete with Lilly’s Zepbound

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...
Crain's New York Business

Pfizer takes small step toward obesity market, but investors question limited trial results

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...